Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 11/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16264708 | 0.85 | HRH4 (0.42) | HRH4CYP17A1CYP3A4HRH3ALDH1A1 | |
| SCHEMBL14415970 | 0.73 | HRH4 (0.44) | HRH4HRH3ALDH1A1MEN1GLA | |
| Hydrochloric Acid SCHEMBL25371613 | 0.72 | HRH4 (0.43) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL14857108 | 0.72 | HRH4 (0.43) | HRH4CYP17A1CYP3A4HRH3ALDH1A1 | |
| SCHEMBL26052366 | 0.70 | HRH1 (0.42) | HRH4HRH3LMNAAPEX1 | |
| SCHEMBL26812529 | 0.70 | HRH4 (0.42) | HRH4CYP17A1CYP3A4HRH3ALDH1A1 | |
| SCHEMBL22082313 | 0.68 | CPB1 (0.41) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL14857315 | 0.67 | HRH3 (0.39) | HRH4CYP17A1CYP3A4HRH3ALDH1A1 | |
| SCHEMBL20696520 | 0.67 | HRH3 (0.44) | HRH4CYP3A4HRH3CYP1A2 | |
| SCHEMBL27617871 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | HRH4 634/4885CYP17A1 2911/4885CYP3A4 3869/4885 |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HRH4 634/4885CYP17A1 2911/4885CYP3A4 3869/4885 |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HRH4 634/4885CYP17A1 2911/4885CYP3A4 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.